Answers are grounded in this paper and cite their sources.
Prospective study demonstrates elimination of abacavir hypersensitivity reactions through HLA-B*5701 genetic testing in French HIV patients, highlighting the value of routine pre-treatment screening.
The association of human leukocyte antigen-B*5701 with abacavir hypersensitivity varies depending on ethnic origin. We confirmed the high specificity of B*5701 in the ethnically mixed French population and used a rapid and inexpensive polymerase chain reaction strategy to evaluate the predictiveness of B*5701 screening. The incidence of hypersensitivity decreased from 12% before screening to 0% after screening, and the rate of unwarranted interruptions of abacavir therapy decreased from 10.2% to 0.73%. We therefore recommend the implementation of this cost-effective screen before treatment with abacavir.
No takes yet. Share an insight, caveat, or question.
Zucman et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: